Lupin’s US subsidiary, Lupin Pharmaceuticals has received final approval for its Rifampin capsules USP, 150 mg and 300 mg strengths from the United States Food and Drugs Administration (US FDA). Lupin’s Rifampin Capsules USP, 150 mg and 300 mg are the AB-rated generic equivalent of Sanofi Aventis’ Rifadin Capsules 150 mg and 300 mg strengths.
Rifampin capsules is indicated for the treatment of all forms of tuberculosis for the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. Rifadin capsules had annual US sales of approximately $18.5 million.
EP News Bureau – Mumbai